Abstract P152: Racial Disparities In The Prevalence Of Peripheral Artery Disease And Diabetes And Amputation Rates Among Medicare Patients

Circulation ◽  
2020 ◽  
Vol 141 (Suppl_1) ◽  
Author(s):  
Mark A Eid ◽  
J Aaron Barnes ◽  
Zachary Wanken ◽  
David H Stone ◽  
Bjoern Suckow ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Average Rate ◽  
Peripheral Artery ◽  
Black Patients ◽  
Hospital Referral ◽  
Increased Risk ◽  
Patients With Diabetes ◽  
Medicare Patients ◽  
Artery Disease ◽  
Using Data

Background: Patients with peripheral artery disease (PAD) and diabetes are at increased risk for nontraumatic amputations. The associations of race with amputation risk among patients with both PAD and diabetes is not well understood in recent national patient cohorts. Methods: Using data from the Centers for Medicare and Medicaid Services from 2007-2016, we identified a cohort of patients concurrently diagnosed with both PAD and diabetes (N= 10,506,254). Patients were followed from time of diagnosis to identify major and minor amputation events, and stratified by race (Black, White, Hispanic) in order to determine differences in outcomes. We examined associations between the regional prevalence of PAD and diabetes and amputation rates, at the level of the state and the hospital referral region (HRR). Results: The average rate of amputation between 2007 and 2016 was 0.3 amputations per 1000 Medicare patients. When analyzed by race, Black patients had an almost 3-fold higher rate of amputation as compared to White patients (0.89 v 0.36 per 1000 patients, P<0.001) and a 2-fold higher rate as compared to Hispanic patients (0.89 v 0.39 per 1000 patients, P<0.001). States with larger populations of Black patients with diabetes and PAD had higher rates of amputation. We also observed a direct and significant association between regional prevalence of PAD and diabetes and amputation risk for both White and Black patients (R 2 =0.36 and 0.25 respectively); some states such as Mississippi had disproportionately higher amputations rates among Black patients for a given prevalence of PAD and diabetes (Figure 1). Conclusion: Black patients with PAD and diabetes are at disproportionally higher risk for amputation. Moreover, regional prevalence of concomitant PAD and diabetes is closely related to amputation risk across races.

Abstract P363: Regional And Racial Variation In The Prevalence Of Concomitant Diabetes And Peripheral Artery Disease

Circulation ◽  
2020 ◽  
Vol 141 (Suppl_1) ◽  
Author(s):  
J Aaron Barnes ◽  
Mark A Eid ◽  
Zachary J Wanken ◽  
Richard J Powell ◽  
David H Stone ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Relative Reduction ◽  
Peripheral Artery ◽  
Racial Variation ◽  
Entire Cohort ◽  
Black Patients ◽  
Hospital Referral ◽  
Medicare Patients ◽  
Artery Disease ◽  
Absolute Decrease

Introduction and Objectives: Prior research has demonstrated regional and racial variation in the prevalence of concomitant diabetes and peripheral artery disease (PAD). However, trends in prevalence of diabetes and PAD across races has not been well explored in recent patient cohorts. Methods: Using data from the Centers for Medicare and Medicaid Services from 2003-2016, we identified patients concurrently diagnosed with both diabetes and PAD (n=10,506,254). Overall prevalence of concomitant diabetes and PAD was determined. Regional variation at the state and hospital referral region (HRR) level was then identified using zip code data. Racial demographics within Medicare data were used to stratify prevalence by race. Results: The overall prevalence of diabetes and PAD across the entire cohort was 15.3 per 1,000 Medicare patients. When stratified by HRR, prevalence of patients with concomitant diabetes and PAD varied by nearly 7-fold with a low of 5.0 and a high of 33.2 per 1,000 Medicare patients. When stratified by race, the number of new patients concomitantly diagnosed with diabetes and PAD decreased across all races, with the greatest decline seen in the Hispanic population (absolute decrease 1.84%, relative reduction 63%). The number of new black patients decreased as well (absolute decrease 1.40%, relative reduction 52%), but blacks continue to comprise the highest proportion of newly diagnosed patients at 1.29% (Figure 1). Conclusion: Significant regional and racial variation exists in the prevalence of concomitant diabetes and PAD diagnoses among Medicare patients with black patients remaining disproportionately affected. Efforts to improve prevention and care management should target these endemic regions and populations.

Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence

2019 ◽  
Vol 24 (38) ◽  
pp. 4511-4515 ◽  
Author(s):  
A. Koutsoumpelis ◽  
C. Argyriou ◽  
K.M. Tasopoulou ◽  
E.I. Georgakarakos ◽  
G.S. Georgiadis
Keyword(s):  
Peripheral Artery Disease ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Current Evidence ◽  
Peripheral Artery ◽  
Cardiac Events ◽  
Traditional Therapy ◽  
Cardiovascular Morbidity And Mortality ◽  
Increased Risk ◽  
Artery Disease

Background: Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality. In addition, the progression of peripheral artery disease leads to an increased risk of limb loss. In order to reduce these events, the benchmark of treatment and research over the last years has been the antiplatelet therapy which aims at inhibition of platelet aggregation. Over the last years, new studies combining antiplatelet agents in different therapeutic schemes have been proven efficacious. Unfortunately, patients remain still at high risk of CV events. Novel Oral Anticoagulants have been introduced as alternatives to warfarin, in the prevention and treatment of venous thromboembolism. The rationale of using medication which acts on platelet activation and the coagulation pathway of thrombosis has led investigators to examine the role of Noac's in preventing CV events in patients with peripheral artery disease, stable or unstable. Methods: The aim of this study is to review the current evidence with respect to recently published studies concerning the use of Novel anticoagulants in peripheral artery disease. Results: The Compass trial has shown that a combination of rivaroxaban with traditional therapy may produce promising results in reducing amputation rates, stroke, cardiac events, and mortality, however, there are still safety issues with bleeding requiring acute care. The ePAD study has provided us with insight concerning safety and efficacy after peripheral angioplasty or stenting and actually the need for further research. The Voyager Pad study, following the steps of Compass, is studying the effect and safety of the addition of rivaroxaban to traditional therapy in the highest risk population aka patients undergoing peripheral revascularization. The evidence concerning patients with concomitant atrial fibrillation appears to be insufficient, however, recent guidelines propose the use of novel oral anticoagulants. Conclusion: For the time being, novel oral anticoagulants in combination with aspirin may provide an alternative treatment in PAD, however, it is deemed necessary to identify patient subgroups who will benefit the most.

A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease

Angiology ◽  
2019 ◽  
Vol 71 (4) ◽  
pp. 303-314
Author(s):  
Rupert Bauersachs ◽  
Sebastian Debus ◽  
Mark Nehler ◽  
Maria Huelsebeck ◽  
Janita Balradj ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Disease Burden ◽  
Ankle Brachial Index ◽  
Peripheral Artery ◽  
Economic Burden Of Disease ◽  
Surgical Interventions ◽  
Treatment Practice ◽  
Patient Profile ◽  
Increased Risk ◽  
Artery Disease

Patients with peripheral artery disease (PAD) have an increased risk of cardiovascular (CV) and limb events, but the disease is frequently underdiagnosed and treatment options are limited. This review examines the disease burden of symptomatic PAD as well as key guideline recommendations. Publications were identified using the ProQuest portal to access the Medline, Medline In-Process, and Embase databases. Search terms for symptomatic PAD were combined with terms relevant to epidemiology, burden, treatment practice, and physiopathology. Articles in English published between January 2001 and September 2016 were screened according to the population, interventions, comparator, outcomes, and study design criteria. Relevant publications (n = 200) were identified. The reported incidence and prevalence of PAD varied depending on the definitions used and the study populations. Patients generally had a poor prognosis, with an increased risk of mortality, CV, and limb events and decreased quality of life. Guideline recommendations included ankle–brachial index measurements, exercise testing, and angiography for diagnosis and risk factor modification, antiplatelets, cilostazol, exercise therapy, or surgical interventions for treatment, depending on the patient profile. The clinical, humanistic, and economic burden of disease in patients with symptomatic PAD is substantial and needs to be reduced through improved PAD management.

scholarly journals Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Elena M. Yubero-Serrano ◽  
Juan F. Alcalá-Diaz ◽  
Francisco M. Gutierrez-Mariscal ◽  
Antonio P. Arenas-de Larriva ◽  
Patricia J. Peña-Orihuela ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Secondary Prevention ◽  
Peripheral Artery Disease ◽  
Cholesterol Efflux ◽  
Newly Diagnosed ◽  
Peripheral Artery ◽  
Cholesterol Efflux Capacity ◽  
Increased Risk ◽  
Artery Disease

Abstract Background Peripheral artery disease (PAD) is recognized as a significant predictor of mortality and adverse cardiovascular outcomes in patients with coronary heart disease (CHD). In fact, coexisting PAD and CHD is strongly associated with a greater coronary event recurrence compared with either one of them alone. High-density lipoprotein (HDL)-mediated cholesterol efflux capacity (CEC) is found to be inversely associated with an increased risk of incident CHD. However, this association is not established in patients with PAD in the context of secondary prevention. In this sense, our main aim was to evaluate the association between CEC and PAD in patients with CHD and whether the concurrent presence of PAD and T2DM influences this association. Methods CHD patients (n = 1002) from the CORDIOPREV study were classified according to the presence or absence of PAD (ankle-brachial index, ABI ≤ 0.9 and ABI > 0.9 and < 1.4, respectively) and T2DM status. CEC was quantified by incubation of cholesterol-loaded THP-1 cells with the participants' apoB-depleted plasma was performed. Results The presence of PAD determined low CEC in non-T2DM and newly-diagnosed T2DM patients. Coexisting PAD and newly-diagnosed T2DM provided and additive effect providing an impaired CEC compared to non-T2DM patients with PAD. In established T2DM patients, the presence of PAD did not determine differences in CEC, compared to those without PAD, which may be restored by glucose-lowering treatment. Conclusions Our findings suggest an inverse relationship between CEC and PAD in CHD patients. These results support the importance of identifying underlying mechanisms of PAD, in the context of secondary prevention, that provide potential therapeutic targets, that is the case of CEC, and establishing strategies to prevent or reduce the high risk of cardiovascular events of these patients. Trial registrationhttps://clinicaltrials.gov/ct2/show/NCT00924937. Unique Identifier: NCT00924937

INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR AND LIMB EVENTS IN MEDICARE PATIENTS WITH PERIPHERAL ARTERY DISEASE

2018 ◽  
Vol 71 (11) ◽  
pp. A2080
Author(s):  
Jeremy Van't Hof ◽  
Marc P. Bonaca ◽  
Eric Weinhandl ◽  
Niki Oldenburg ◽  
Monica Chase ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Medicare Patients ◽  
Artery Disease

scholarly journals Lower Limb Amputations in Patients With Diabetes and Peripheral Artery Disease: A Time-Series Analysis of Trends (2005-2016)

2018 ◽  
Vol 68 (3) ◽  
pp. e83-e84
Author(s):  
Mohamad A. Hussain ◽  
Mohammed Al-Omran ◽  
Konrad Salata ◽  
Jack V. Tu ◽  
Atul Sivaswamy ◽  
...  
Keyword(s):  
Time Series ◽  
Time Series Analysis ◽  
Peripheral Artery Disease ◽  
Lower Limb ◽  
Peripheral Artery ◽  
Series Analysis ◽  
Patients With Diabetes ◽  
Artery Disease

scholarly journals Genetic Variation in Blood Pressure and Lifetime Risk of Peripheral Artery Disease: A Mendelian Randomization Study

2020 ◽  
Author(s):  
Michael G Levin ◽  
Derek Klarin ◽  
Venexia M Walker ◽  
Dipender Gill ◽  
Julie Lynch ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Calcium Channel ◽  
Peripheral Artery Disease ◽  
Genetic Correlations ◽  
Channel Blockers ◽  
Peripheral Artery ◽  
Antihypertensive Medications ◽  
Increased Risk ◽  
Genes Encoding ◽  
Artery Disease

Aims: We aimed to estimate the effect of blood pressure and blood pressure lowering medications (via genetic proxies) on peripheral artery disease. Methods and Results: GWAS summary statistics were obtained for BP (International Consortium for Blood Pressure + UK Biobank GWAS; N = up to 757,601 individuals), peripheral artery disease (PAD; VA Million Veteran Program; N = 24,009 cases, 150,983 controls), and coronary artery disease (CAD; CARDIoGRAMplusC4D 1000 Genomes; N = 60,801 cases, 123,504 controls). Genetic correlations between systolic BP (SBP), diastolic BP (DBP), pulse pressure (PP) and CAD and PAD were estimated using LD score regression. The strongest correlation was between SBP and CAD (rg = 0.36; p = 3.9 x 10-18). Causal effects were estimated by two-sample MR using a range of pleiotropy-robust methods. Increased SBP, DBP, and PP increased risk of both PAD (SBP OR 1.25 [1.19-1.31] per 10mmHg increase, p = 3 x 10-18; DBP OR 1.27 [1.17-1.39], p = 4 x 10-8; PP OR 1.51 [1.38-1.64], p = 1 x 10-20) and CAD (SBP OR 1.37 [1.29-1.45], p = 2 x 10-24; DBP OR 1.6 [1.45-1.76], p = 7 x 10-22; PP OR 1.56 [1.4-1.75], p = 1 x 10-15). The effects of SBP and DBP were greater for CAD than PAD (pdiff = 0.024 for SBP, pdiff = 4.9 x 10-4 for DBP). Increased liability to PAD increased PP (beta = 1.04 [0.62-1.45] mmHg per 1 unit increase in log-odds in liability to PAD, p = 1 x 10-6). MR was also used to estimate the effect of BP lowering through different classes of antihypertensive medications using genetic instruments containing BP-trait associated variants located within genes encoding protein targets of each medication. SBP lowering via calcium channel blocker-associated variants was protective of CAD (OR 0.38 per 10mmHg decrease in SBP; 95% CI 0.19-0.77; p = 0.007). Conclusions: Higher BP is likely to cause both PAD and CAD but may have a larger effect on CAD risk. BP-lowering through calcium-channel blockers (as proxied by genetic variants) decreased risk of CAD.

Abstract 3073: Metabolic Syndrome, Inflammation and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
David Conen ◽  
Kathryn M Rexrode ◽  
Paul M Ridker ◽  
Aruna D Pradhan
Keyword(s):  
Metabolic Syndrome ◽  
Peripheral Artery Disease ◽  
Cox Proportional Hazards ◽  
Health Study ◽  
Intercellular Adhesion Molecule ◽  
Peripheral Artery ◽  
Risk Increase ◽  
Increased Risk ◽  
Multivariable Models ◽  
Artery Disease

Background Metabolic syndrome (MetS) includes a number of cardiovascular risk factors known to predict vascular disease. Little is known, however, about the interrelationships between MetS, inflammation and the risk of incident peripheral artery disease (PAD). Methods We conducted a prospective cohort study among 27111 women participating in the Women’s Health Study. Subjects were free of cardiovascular disease at baseline and followed for the incidence of symptomatic PAD (n=114) over a follow-up period of 13.3 years. We used Cox proportional-hazards models to compare the risk of PAD among women with and without the MetS. We also evaluated relationships between MetS and markers of subclinical inflammation including high sensitivity C-reactive protein (hsCRP) and soluble intercellular adhesion molecule-1 (sICAM-1) and adjusted for these biomarker levels in multivariable models. Results At study entry, 25.5% of participants had the MetS. Women with the MetS had a 62% increased risk of incident PAD (HR 1.62; 95% CI 1.10 –2.38). After multivariable adjustment, MetS remained significantly associated with incident PAD (Table ). Similar results were obtained when we assessed the risk of PAD according to the number of MetS defining traits (21% risk increase per additional trait) (Table ). Median plasma levels of hsCRP and sICAM-1 were 4.0 mg/L versus 1.53 mg/L (p<0.0001) and 374 ng/mL versus 333 ng/mL (p<0.0001) in women with and without MetS, respectively. From 0 to 5 MetS defining traits, median hsCRP levels gradually increased from 1.0 to 5.9 mg/L (p<0.0001) and median sICAM-1 levels increased from 321 to 413 ng/mL (p<0.0001). When hsCRP and sICAM-1 were added to multivariable models for incident PAD, risk estimates for the MetS were substantially attenuated and became non-significant (Table ). Conclusion Women with the MetS have an increased risk of incident PAD. This increased risk may be largely mediated by the effects of inflammation and/or endothelial activation. Metabolic Syndrome and Risk of PAD

Sign in / Sign up

Export Citation Format

Share Document